Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02133196CT.gov T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adenosquamous Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Young Til (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Cis-Diamminedichloroplatinum Ii | Barbara Ann Karmanos Cancer Institute | P3 | BB |
| Carboplatin | NRG Oncology | P3 | BB |
| Gefitinib | National Cancer Institute (NCI) | P3 | BB |
| Vinorelbine Ditartrate | National Cancer Institute (NCI) | P3 | BB |
| Shark Cartilage Extract | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
| Docetaxel | Wake Forest University Health Sciences | P2 | B |
| Cetuximab | National Cancer Institute (NCI) | P2 | B |
+14 more in the Adenosquamous Lung Carcinoma cohort
Other indications for Young Til
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Skin Cancer | — | P2 | B · 57 |
| Metastatic Melanoma | — | P2 | B · 57 |
| Vaginal Cancer | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Young Til in Adenosquamous Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/young-til-adenosquamous-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →